3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Carcinoma in Situ
1
Interventions
valrubicin
1
temsirolimus
1
pembrolizumab
1
palbociclib
1
niraparib
1
enfortumab vedotin
1
cabozantinib
1
atezolizumab
1
Zoledronic Acid
1
Valproic Acid
1
VMBP protocol
1
Trastuzumab
1
Sunitinib
1
Standard of Care
1
Sirolimus
1
Prednisone
1
Nivolumab
1
Mitomycin
1
Immunoglobulin G
1
Gemcitabine
1
Etoposide
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cisplatin
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urologic Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA